Optigenex Inc. says a human trial involving healthy adults found statistically significant improvements in attention, memory, executive function and social cognition after daily intake of ac-11®. According to the company these results emerge from a randomized, double-blind, placebo-controlled, cross…
Elissa Kawamoto, Audiologist at HearUSA, discusses how early hearing care supports brain health and lowers dementia risk. September is World Alzheimer’s Month, which is a good reminder of how important it is to protect our brain health long before problems arise. While many associate mental wellness…
Minovia Therapeutics Ltd. said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its investigational therapy, MNV-201, for the treatment of Myelodysplastic Syndrome (MDS), a serious age-related hematopoietic disease. The company said that this designation follows…
Stealth BioTherapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Forzinity (elamipretide HCl), marking it as the first approved therapy for Barth syndrome. This ultra-rare genetic mitochondrial disorder primarily affects males and is characte…
Telomir Pharmaceuticals has announced new in vitro data demonstrating that its lead drug candidate, Telomir-1, inhibits three members of the KDM5 histone demethylase family. These enzymes are implicated in silencing tumor suppressor genes and activating inflammatory pathways, processes associated wi…
Lifespan Research Institute (LRI) has introduced the Public Longevity Group (PLG), aiming to bridge the gap between scientific advancements in aging and public acceptance. The initiative focuses on developing data-driven tools to assess and enhance public trust in longevity science. To support this …
New program combines supplements, prescriptions and longitudinal monitoring as longevity companies push further into healthcare delivery. Elysium Health is stretching its footprint. Moving past consumer retail, the New York-based firm has unveiled The Elysium Longevity Institute (TELI) – a physician…
From ovarian aging to healthcare access, the finalists reflect a longevity sector that is broadening in both scope and ambition. The Longevity Show has announced the five finalists selected to compete in its inaugural Pitch Competition, with companies spanning therapeutics, nutrition, digital health…
Lindus Health and Frieda Health have concluded a clinical trial assessing the Frieda Menova app, a digital therapeutic integrating cognitive behavioral therapy (CBT) aimed at alleviating menopausal symptoms. The open-label pilot study involved 100 participants with physician-confirmed natural menopa…
New research reveals how different tissues age at different rates, opening possibilities for targeted healthspan interventions. Aging is neither uniform nor orderly, yet most biological clocks attempt to distill it into a single figure – neat, marketable and often misleading. A study led by research…
Until Labs targets organ transplantation bottlenecks as a first step towards whole-body reversible cryopreservation. Cryonics startup Until Labs has closed a $58 million Series A financing round, bringing its total raised to over $100 million as it works to build technology for reversible cryopreser…
BlueRock Therapeutics has treated the first patient in its Phase III exPDite-2 trial of bemdaneprocel, an investigational cell therapy for Parkinson’s disease, according to the company. The therapy, derived from allogeneic pluripotent stem cells, is designed to replace dopamine-producing neurons los…
Cerevance said it will present results from its Phase 2 ASCEND trial of solengepras at the 2025 International Congress of Parkinson’s Disease and Movement Disorders, taking place October 5–9 in Honolulu. According to the company, the data include assessments of functional and non-motor outcomes, alo…
Elektra Health, a virtual menopause care provider, announced the expansion of its insurance network in New York State, now adding Fidelis Care and MetroPlusHealth plans starting September 1. The company said that with these additions, its coverage now reaches more than 95 % of women insured under co…
InBrain Pharma will present long-term follow-up data from its Phase I/II DIVE-I study at the International Conference of Parkinson’s Disease and Movement Disorders (MDS) 2025, to be held October 5–9 in Honolulu, Hawaii, the company said. The oral presentation is scheduled for October 8 at 12:00 pm (…
AI-designed ‘companion therapeutic’ works alongside GLP-1 therapy through a complementary mechanism linked to healthy aging. Hot on the heels of multiple references to GLP-1 receptor agonists as longevity drugs at the recent Aging Research and Drug Discovery meeting in Copenhagen, AI-pow…
New interventions on pump.science aim to push lifespan extension beyond single pathways and into bold combination therapies. Rapamycin has long been the poster child of geroscience, reliably extending lifespan in multiple species and producing an enviable array of healthspan benefits; yet no single …
Allen Law sees accessible clinics, science and shopping combined in his vision for a new era of everyday longevity. When it comes to longevity, infrastructure is the new frontier; the sector is expanding into the spaces where people live, work and gather, and in doing so it is reshaping how preventi…
CellProthera announced that the results from its EXCELLENT Phase I/IIb trial of ProtheraCytes® have now been published in JACC: Heart Failure, offering the first peer-reviewed evidence on the therapy’s safety and feasibility in patients with severe heart failure following myocardial infarction. The …
United Space Structures Founder Bill Kemp on why governments must treat aging itself as the world’s greatest health challenge. Our healthcare systems are fighting an unwinnable war. Year after year, trillions are spent managing the symptoms of chronic disease – heart disease, cancer, diabetes, Alzhe…
